Skip to main content
. 2021 Apr 15;106(8):2121–2130. doi: 10.3324/haematol.2020.263392

Figure 3.

Figure 3.

Survival of patients with FLT3- ITD+ relapsed/refractory acute myeloid leukemia given first salvage treatment with quizartinib in combination with azacitidine or low-dose cytarabine. (A) Overall survival. (B) Relapse-free survival. Quiz: quizartinib; AZA: azacitidine; LDAC: low-dose cytarabine; mo: months.